Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study
-
By
-
Yuanyuan Zheng
-
Yizhen Chen
-
Wei Lin
-
Le Min
-
June 8, 2026
-
Clinical Scorecard: Linking Tumor Genomic Alterations to the Risk of Hypophysitis Induced by PD-1 Inhibitors: A Retrospective Cohort Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Higher tumor mutational burden and specific gene mutations |
| Target Population | Adults with breast cancer, lung cancer, renal cell carcinoma, or melanoma receiving PD-1 inhibitors |
| Care Setting | |
Key Highlights
- Higher overall tumor mutational burden in hypophysitis group (6.02 vs. 5.19 mut/Mb, P = 0.002)
- Significant mutations in BABAM1, KDM5C, CDH4, and TAL1 in the hypophysitis group
- PAXIP1 mutations more common in non-hypophysitis group (19.6% vs. 0%, P = 0.037)
Guideline-Based Recommendations
Diagnosis
- Confirm diagnosis of hypophysitis based on clinical and imaging data
Management
- Hormone replacement therapy for patients with confirmed ACTH deficiency should be based on clinical guidelines
Monitoring & Follow-up
- Implement individualized endocrine monitoring strategies during immunotherapy
Risks
- Risk of adrenal crisis due to unrecognized ACTH deficiency
Patient & Prescribing Data
Adults with breast cancer, lung cancer, renal cell carcinoma, or melanoma
PD-1 inhibitors (pembrolizumab or nivolumab) used as monotherapy
Clinical Best Practices
- Monitor for signs of endocrine dysfunction in patients treated with PD-1 inhibitors
Related Resources & Content
